#USA #Citius Pharmaceuticals #Mino-Lok #LYMPHIR #Cranford, N.J.

Citius Pharmaceuticals Reports Fiscal Q3 2025 Financial Results and Business Update

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a biopharmaceutical company focused on developing critical care products, has reported its financial results for the fiscal third quarter ending June 30, 2025. The company is gearing up for a full-scale commercial rollout of its innovative oncology product, LYMPHIR™, while also updating investors on its financial health and strategic initiatives.

Financial Highlights

During the third quarter, Citius successfully raised $12.5 million in gross financing, supplementing this with an additional $9 million from its oncology division in July 2025. This capital is primarily aimed at facilitating pre-launch preparations for LYMPHIR, which is set for U.S. introduction in the fourth quarter of 2025. Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, stated: "We believe we are now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial organization."

Key financial metrics include:

• - Research and Development (R&D) expenses were $1.6 million, down from $2.8 million during the same quarter last year.
• - General and Administrative (GA) expenses fell to $4.4 million from $4.8 million.
• - Net loss decreased to $9.2 million or ($0.80) per share, compared to a net loss of $10.6 million or ($1.57) per share in Q3 2024.

Cash Position
Citius Pharmaceuticals reported that as of June 30, 2025, it held $6.1 million in cash and equivalents, which will support ongoing operations. The company has raised a total of $16.5 million through equity and $1 million from a note payable in the last nine months. Notably, a public offering by Citius Oncology on July 17, 2025, yielded $7.4 million in net proceeds.

Business Updates

Citius is currently finalizing critical launch activities for LYMPHIR™, such as commercial-scale manufacturing, packaging, labeling, and distribution agreements with leading specialty pharmaceutical partners. This product targets patients suffering from cutaneous T-cell lymphoma, a demographic seeking new therapeutic options.

In addition to LYMPHIR™, Citius is also advancing its antibiotic lock solution, Mino-Lok, designed to mitigate catheter-related bloodstream infections. The company is in close communication with the U.S. Food and Drug Administration (FDA) to determine the path forward for this potential game-changing product.

Looking Forward

The substantial progress Citius Pharmaceuticals made over the past quarter demonstrates its commitment to advancing healthcare innovation. The company’s dual focus on LYMPHIR™ and Mino-Lok places it in a strong position within the biopharmaceutical landscape.

As Citius moves toward commercialization and faces the necessary regulatory and market challenges, the upcoming months will be critical for the company's growth strategy and continued investor engagement. For more detailed information on the full financial results, stakeholders can refer to the Quarterly Report on Form 10-Q filed with the SEC.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals is dedicated to the development and commercialization of first-in-class critical care products. Its late-stage pipeline includes LYMPHIR™, Mino-Lok®, and CITI-002 (Halo-Lido), reinforcing its commitment to addressing unmet medical needs in various therapeutic areas. To learn more about their innovative products, visit Citius Pharma’s website.